BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao WH, Li MH, Pan CQ, Lu Y, Zhang L, Ran CP, Wu SL, Hua WH, Liu SA, Shen G, Chang M, Liu RY, Hao HX, Hu LP, Xie Y. Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy. J Interferon Cytokine Res 2018;38:197-205. [PMID: 29791282 DOI: 10.1089/jir.2018.0014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Gao Y, Yang L, Lin Y, Deng W, Jiang T, Bi X, Lu Y, Zhang L, Shen G, Liu R, Wu S, Chang M, Xu M, Hu L, Song R, Jiang Y, Yi W, Xie Y. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B. Front Immunol 2022;13:1024333. [DOI: 10.3389/fimmu.2022.1024333] [Reference Citation Analysis]
2 Li M, Xie S, Bi X, Sun F, Zeng Z, Deng W, Jiang T, Lin Y, Yang L, Lu Y, Zhang L, Yi W, Xie Y. An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients. Front Microbiol 2022;13:960589. [DOI: 10.3389/fmicb.2022.960589] [Reference Citation Analysis]
3 Cao W, Xie S, Zhang L, Bi X, Lin Y, Yang L, Lu Y, Liu R, Chang M, Wu S, Shen G, Dong J, Xie Y, Li M. Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment. Front Immunol 2022;13:891424. [PMID: 35663955 DOI: 10.3389/fimmu.2022.891424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li M, Zhang L, Xie S, Sun F, Zeng Z, Deng W, Jiang T, Bi X, Lin Y, Yang L, Lu Y, Shen G, Liu R, Wu S, Chang M, Hu L, Dong J, Yi W, Xie Y. Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients. Front Immunol 2022;13:892031. [PMID: 35603222 DOI: 10.3389/fimmu.2022.892031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zhou L, He Q, Liu X, Yang X, Ou X, Situ B, Li Y, Pan X, Xu Q. Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse. Med Sci Monit 2022;28:e934785. [PMID: 35351845 DOI: 10.12659/MSM.934785] [Reference Citation Analysis]
6 He Y, Zhou Y, Wang H, Yin J, Chang Y, Hu P, Ren H, Xu H. Identifying potential biomarkers in hepatitis B virus infection and its response to the antiviral therapy by integrated bioinformatic analysis. J Cell Mol Med 2021;25:6558-72. [PMID: 34041839 DOI: 10.1111/jcmm.16655] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Li MH, Chen QQ, Zhang L, Lu HH, Sun FF, Zeng Z, Lu Y, Yi W, Xie Y. Association of cytokines with hepatitis B virus and its antigen. J Med Virol 2020. [PMID: 32662892 DOI: 10.1002/jmv.26301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen Y, Yang JE, Tang JM, Mao QG, Zheng QZ, Zheng Y. Predictive value of plasmacytoid dendritic cells and Toll-like receptor-9 regarding the treatment efficacy of interferon-α in HBeAg-positive chronic hepatitis B patients. Exp Ther Med 2019;18:4541-6. [PMID: 31798696 DOI: 10.3892/etm.2019.8161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Wang J, Yao Y, Chen X, Wu J, Gu T, Tang X. Host derived exosomes-pathogens interactions: Potential functions of exosomes in pathogen infection. Biomedicine & Pharmacotherapy 2018;108:1451-9. [DOI: 10.1016/j.biopha.2018.09.174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]